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Abstract 13	
Sugar based surfactants conjugated with fatty acid chains are an emerging broad 14	
group of highly biocompatible and biodegradable compounds with established and 15	
potential future applications in the pharmaceutical, cosmetic and food industries. In 16	
this work, we investigated absorption enhancing and antimicrobial properties of 17	
disaccharide lactose, mono-esterified with unsaturated fatty acids through an 18	
enzymatic synthetic approach. After chemical and cytotoxicity characterizations, their 19	
permeability enhancing activity was demonstrated using intestinal Caco-2 monolayers 20	
through transepithelial electrical resistance (TEER) and permeability studies. The 21	
synthesised compounds, namely lactose palmitoleate (URB1076) and lactose 22	
nervonate (URB1077), were shown to exhibit antimicrobial activity versus eight 23	
pathogenic species belonging to Gram-positive, Gram-negative microorganisms and 24	
fungi.  25	
 26	
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1. Introduction 33	
Over the past few decades there has been a growing interest on sugar-based 34	
surfactants due to the large range of applications, from the biomedical field to 35	
cosmetics and food industries [1,2]. This class of molecules are generally classified as 36	
biocompatible and biodegradable non-ionic surfactants with emulsifying and 37	
antimicrobial abilities [3,4]. Their surface-active properties and applications are 38	
mainly influenced by the nature of the sugar headgroup (e.g. mono-, di- or 39	
polysaccharides), the carbon chain length and the degree of substitution [5]. 40	
The increasing demand for healthy and non-toxic additives has intensified the need 41	
for, and research on, novel compounds for food, medical and pharmaceutical 42	
applications. In this context, the development of sugar-fatty acid esters is becoming 43	
increasingly attractive. Among their possible applications, absorption-enhancing 44	
potential for biologics delivery has been recently evaluated [6,7]. 45	
Biological therapeutics (biologics) have and will continue to have a major impact on 46	
the management of a number of diseases. While their therapeutic potential is often 47	
unmatched by small drug molecules, biologics suffer from injection-only 48	
administration. Non-invasive delivery of this class of therapeutics is highly attractive. 49	
However, drug delivery technologies, which offer the possibility to achieve safe and 50	
clinically relevant non-invasive delivery of biologics, are currently lacking. The key 51	
challenge to achieving this is a poor permeation of therapeutic macromolecules across 52	
the mucosal surfaces [8], which have evolved as biological structures presenting a 53	
barrier to the movement of material from the external environment into the systemic 54	
circulation.  55	
The use of absorption enhancing agents is a common approach utilised to improve 56	
mucosal absorption (and hence the resulting bioavailability) of biologics following 57	
mucosal administration [8–11]. While the use of absorption enhancing agents offers 58	
significant potential in enabling non invasive delivery of biologics, ‘absorption 59	
enhancers’, which are chemically diverse compounds exerting their absorption-60	
enhancing effect through different mechanism(s), have often been associated with 61	
unacceptable toxicity profile [12]. Absorption enhancers that are capable of improving 62	
the mucosal absorption of biotherapeutics in a safe and therapeutically-effective 63	
manner are highly desirable, but the search for these continues [13–15].  64	
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In this study we synthetized and characterized lactose palmitoleate and lactose 65	
nervonate, two new biodegradable lactose esters based on unsaturated fatty acids, 66	
namely palmitoleic (C16:1ω7) and nervonic (C24:1ω9) acids. The cytotoxicity of 67	
these compounds was evaluated in vitro and associated to the capacity to act as oral 68	
absorption enhancers of biotherapeutics as tested on the intestinal Caco-2 monolayers. 69	
Additionally, the compounds were also evaluated for antimicrobial activity by testing 70	
minimum inhibitory concentration (MIC) and effect on the growth inhibition of 71	
several pathogenic microorganisms. 72	
 73	
2. Experimental section  74	
2.1 Chemicals, materials and methods. 75	
Palmitoleic acid and nervonic acid were purchased from TCI, lactose monohydrate 76	
from Carlo Erba, while Lipozyme® (immobilized from Mucor miehei), p-77	
toluenesulfonic acid, 2,2-dimethoxypropane, tetrafluoroboric acid diethyl ether 78	
complex and all organic solvents used in this study were purchased from Sigma. Prior 79	
to use, acetonitrile was dried with molecular sieves with an effective pore diameter of 80	
4 Å and toluene was saturated with water. Caco-2 cells were obtained from the 81	
European Collection of Cell Cultures. Dulbecco’s Modified Eagles Medium 82	
(DMEM), Hank’s Balanced Salt Solution (HBSS, with sodium bicarbonate and 83	
without phenol red), non-essential amino acids (100%), L-glutamine (200 mM), fetal 84	
bovine serum (FBS), antibiotic/antimycotic solution (10–12,000 U/mL penicillin, 10–85	
12 mg/mL streptomycin, 25–30 µg/mL amphotericin B), trypsin–EDTA solution (2.5 86	
mg/mL trypsin, 0.2 mg/mL EDTA) and fluorescein isothiocyanate-labelled ovalbumin 87	
(FITC-OVA) were supplied by Sigma (Poole, UK). MTS reagent, 3-(4,5-88	
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 89	
(commercially known as CellTiter96® AQueous One Solution Cell Proliferation Assay) 90	
was purchased from Promega (USA). Tissue culture flasks (75 cm3 with ventilated 91	
caps), black 96-well plates and Transwell® inserts (12 mm diameter, 0.4 µm pore size, 92	
were purchased from Corning (USA). All other chemicals (reagent grade) were 93	
purchased from Sigma. Ultrapure chitosan chloride of 213 kDa average molecular 94	
weight (‘Protasan UP CL 213’) was obtained from Novamatrix (Denmark). Thermal 95	
analysis was carried out using differential scanning calorimetry (DSC). DSC analysis 96	
was performed using a DSC 8500 (Perkin-Elmer, Norwalk, USA) equipped with an 97	
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intracooler (Intracooler 2, Perkin-Elmer, Norwalk, USA) and analyzed in an inert N2 98	
atmosphere. The structures of compounds were unambiguously assessed by MS, 1H 99	
NMR, 13C NMR, and IR. ESI-MS spectra were recorded with a Waters Micromass 100	
ZQ spectrometer in a negative or positive mode using a nebulizing nitrogen gas at 400 101	
L/min and a temperature of 250 °C, cone flow 40 mL/min, capillary 3.5 Kvolts and 102	
cone voltage 60 V; only molecular ions [M-H]– or [M+NH4]+ are given. 1H NMR and 103	
13C NMR spectra were recorded on a Bruker AC 400 or 101, respectively, 104	
spectrometer and analyzed using the TopSpin software package. Chemical shifts were 105	
measured by using the central peak of the solvent. IR spectra were obtained on a 106	
Nicolet Atavar 360 FT spectrometer. Column chromatography purifications were 107	
performed under “flash” conditions using Merck 230–400 mesh silica gel. TLC was 108	
carried out on Merck silica gel 60 F254 plates, which were visualized by exposure to 109	
ultraviolet light and by exposure to an aqueous solution of ceric ammonium 110	
molibdate. 111	
 112	
2.2 Synthesis of lactose-based surfactants 113	
2.2.1 General procedure for the synthesis of lactose tetra acetate esters (Z)-6’-O-114	
hexadec-9-enoyl- and (Z)-6’-O-tetracos-15-enoyl-4-O-(3’,4’-O-isopropylidene-β-115	
D-galactopyranosyl)-2,3:5,6-di-O-isopropylidene-1,1-di-O-methyl-D-116	
glucopyranose (3a,b). 117	
Lipozyme® (0.078 g) was added to a solution of palmitoleic acid (1a) or nervonic acid 118	
(1b) (0.79 mmol) and 4-O-(3’,4’-O-isopropylidene-β-D-galactopyranosyl)-2,3:5,6-di-119	
O-isopropylidene-1,1-di-O-methyl-D-glucopyranose (lactose tetra acetate, LTA) [16] 120	
(2) (0.401 g, 0.79 mmol) in water-satured toluene at 25 °C. The mixture was stirred at 121	
75 °C for 12 h, cooled, diluted with acetone, then filtered, and the filtrate was 122	
concentrated. The purification of the residue by column chromatography (petroleum 123	
ether/EtOAc 7:3) gave 3a,b as pale yellow oils.  124	
3a. Yield: 70% (0.413 g). ESI-MS: m/z 744 (M-H)–, 763 (M+NH4)+. 1H NMR 125	
(CD3OD) δ: 0.93 (t, 3H, J = 6.7 Hz, CH3), 1.30–1.38 (m, 22H), 1.39 (s, 3H, CH3), 126	
1.41 (s, 3H, CH3), 1.44 (s, 3H, CH3), 1.49 (s, 3H, CH3), 1.59–1.70 (m, 2H, 127	
CH2CH2COOR), 2.03–2.06 (m, 4H, CH2CH=CHCH2), 2.40 (t, 2H, J = 7.0 Hz, 128	
CH2COOR), 3.45–3.47 (m, 6H, 2 -OCH3), 3.47 (dd, 1H, J8-9 = 7.1 Hz, J8-7 = 8.0 Hz, 129	
H8), 3.91 (dd, 1H, J4-3 = 1.2 Hz, J4-5 = 5.0 Hz, H4), 4.04 (ddd, 1H, J11-12a = 1.5 Hz, J11-130	
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10 = 2.2 Hz, J11-12b = 6.8 Hz, H11), 4.05 (dd, 1H, J6b-5 = 6.0 Hz, J6b-6a = 8.7 Hz, H6b), 131	
4.08 (dd, 1H, J9-10 = 5.5 Hz, J9-8 = 7.1 Hz, H9), 4.14 (dd, 1H, J3-4 = 1.2 Hz, J3-2 = 7.5 132	
Hz, H3), 4.17 (dd, 1H, J6a-5 = 6.0 Hz, J6a-6b = 8.7 Hz, H6a), 4.22 (dd, 1H, J10-11 = 2.2 Hz, 133	
J10-9 = 5.5 Hz, H10), 4.27 (dd, 1H, J12b-11 = 6.8 Hz, J12b-12a = 11.5 Hz, H12b), 4.30 (dd, 134	
1H, J12a-11 = 1.5 Hz, J12a-12b = 11.5 Hz, H12a), 4.31 (ddd, J5-4 = 5.0 Hz, J5-6a ≅ J5-6b = 6.0 135	
Hz, H5), 4.41 (d, 1H, J1-2 = 6.2 Hz, H1), 4.51 (d, 1H, J7-8 = 8.0 Hz, H7), 4.51 (dd, 1H, 136	
J2-1 = 6.2 Hz, J2-3 = 7.5 Hz, H2), 5.35 (ddd, 1H, J22-23a ≅ J22-23b = 6.0 Hz, J22-21 = 11.0 137	
Hz, CH=CH), 5.39 (ddd, 1H, J21-20a ≅ J21-20b = 6.0 Hz, J21-22 = 11.0 Hz, CH=CH) ppm. 138	
13C NMR (CD3OD) δ: 13.0, 22.3, 24.2, 24.6, 25.1, 25.5, 25.7, 26.2, 26.7, 26.8, 27.0, 139	
28.6, 28.76, 28.81, 28.9, 29.39, 29.43, 31.5, 33.5, 53.0, 55.1, 63.1, 65.5, 70.8, 73.3, 140	
73.5, 75.4, 76.4, 76.8, 77.5, 79.4, 103.1, 105.7, 108.5, 109.7, 109.8, 129.4, 129.5, 141	
173.8 ppm. IR (Nujol): 2952, 1729, 1712 cm-1. 142	
3b. Yield: 47% (0.222 g). ESI-MS: m/z 856 (M-H)–, 875 (M+NH4)+. 1H NMR 143	
(CD3OD) δ: 0.93 (t, 3H, J = 6.7 Hz, CH3), 1.30–1.38 (m, 38H), 1.39 (s, 3H, CH3), 144	
1.41 (s, 3H, CH3), 1.44 (s, 3H, CH3), 1.49 (s, 3H, CH3), 1.59–1.70 (m, 2H, 145	
CH2CH2COOR), 2.03–2.08 (m, 4H, CH2CH=CHCH2), 2.40 (t, 2H, J = 7.0 Hz, 146	
CH2COOR), 3.45–3.47 (m, 6H, 2 -OCH3), 3.48 (dd, 1H, J8-9 = 7.1 Hz, J8-7 = 8.0 Hz, 147	
H8), 3.91 (dd, 1H, J4-3 = 1.2 Hz, J4-5 = 5.0 Hz, H4), 4.04 (ddd, 1H, J11-12a = 1.5 Hz, J11-148	
10 = 2.2 Hz, J11-12b = 6.9 Hz, H11), 4.05 (dd, 1H, J6b-5 = 6.0 Hz, J6b-6a = 8.7 Hz, H6b), 149	
4.08 (dd, 1H, J9-10 = 5.6 Hz, J9-8 = 7.1 Hz, H9), 4.14 (dd, 1H, J3-4 = 1.2 Hz, J3-2 = 7.5 150	
Hz, H3), 4.17 (dd, 1H, J6a-5 = 6.0 Hz, J6a-6b = 8.7 Hz, H6a), 4.21 (dd, 1H, J10-11 = 2.2 Hz, 151	
J10-9 = 5.5 Hz, H10), 4.27 (dd, 1H, J12b-11 = 6.9 Hz, J12b-12a = 11.5 Hz, H12b), 4.29–4.33 152	
(m, 2H, H5, H12a), 4.41 (d, 1H, J1-2 = 6.2 Hz, H1), 4.51 (d, 1H, J7-8 = 8.0 Hz, H7), 4.51 153	
(dd, 1H, J2-1 = 6.2 Hz, J2-3 = 7.5 Hz, H2), 5.35 (ddd, 1H, J28-29a ≅ J28-29b = 6.0 Hz, J28-27 154	
= 11.0 Hz, CH=CH), 5.39 (ddd, 1H, J27-26a ≅ J27-26b = 6.0 Hz, J27-28 = 11.0 Hz, 155	
CH=CH) ppm. 13C NMR (CD3OD) δ: 13.1, 22.3, 24.2, 24.6, 25.1, 25.5, 25.7, 26.2, 156	
26.7, 26.7, 26.9, 28.8, 28.9, 28.9, 29.0, 29.1, 29.20, 29.22, 29.33, 29.34, 29.35, 29.4, 157	
29.4, 31.7, 33.5, 53.0, 55.1, 63.1, 65.5, 70.8, 73.3, 73.6, 75.4, 76.4, 76.9, 77.6, 79.4, 158	
103.1, 105.7, 108.4, 109.7, 109.9, 129.5, 129.5, 173.8 ppm. IR (Nujol): 2965, 1731, 159	
1713 cm-1. 160	
2.2.2 General procedure for the synthesis of lactose fatty acid esters (Z)-6’-O-161	
hexadec-9-enoyl- and (Z)-6’-O-tetracos-15-enoyl-4-O-(β-D-galactopyranosyl)-D-162	
glucopyranose (4a,b).  163	
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Compounds 3a or 3b (0.43 mmol) were dissolved in tetrafluoroboric 164	
diethylether/water/acetonitrile (1:5:500) and the mixture was stirred at 30 °C for 2 h. 165	
The products precipitated during the reaction as white solid were subsequently 166	
filtered, washed with acetonitrile, and then dried. The purification by crystallization 167	
from methanol gave the desired compounds as white solids. 168	
4a [(Z)-6’-O-Hexadec-9-enoyl lactose, lactose palmitoleate, URB1076]. Yield: 82% 169	
(0.305 g). Mp: modification of the physico-chemical state starting from 60 °C. ESI-170	
MS: m/z 577 (M-H)–, 596 (M+NH4)+. 1H NMR (CD3OD) δ: 0.91 (t, 3H, J = 7.0 Hz, 171	
CH3), 1.25–1.45 [m, 16H, (CH2)n], 1.57–1.70 (m, 2H, CH2CH2COOR), 1.98–2.12 (m, 172	
4H, CH2CH=CHCH2), 2.39 (t, 2H, J = 7.5 Hz, CH2COOR), 3.42 (dd, 1H, J2-1 = 3.5 173	
Hz, J2-3 = 9.5 Hz, H2), 3.50 (dd, 1H, J4-3 ≅ J4-5 = 9.5 Hz, H4), 3.51 (dd, 1H, J9-10 = 3.0 174	
Hz, J9-8 = 9.8 Hz, H9), 3.58 (dd, 1H, J8-7 = 7.5 Hz, J8-9 = 9.8 Hz, H8), 3.75–3.96 (m, 175	
4H, H5, H11, H6a, H6b), 3.79 (dd, 1H, J3-4 ≅ J3-2 = 9.5 Hz, H3), 3.80 (dd, 1H, J10-9 = 3.0 176	
Hz, J10-11 = 5.0 Hz, H10), 4.26 (dd, 1H, J12b-11 = 5.0 Hz, J12b-12a = 11.5 Hz, H12b), 4.29 177	
(dd, 1H, J12a-11 = 6.5 Hz, J12a-12b = 11.5 Hz, H12a), 4.35 (d, 1H, J7-8 = 7.5 Hz, H7), 5.09 178	
(d, 1H, J1-2 = 3.5 Hz, H1), 5.32 (ddd, 1H, J22-23a ≅ J22-23b = 6.0 Hz, J22-21 = 11.0 Hz, 179	
CH=CH), 5.37 (ddd, 1H, J21-20a ≅ J21-20b = 6.0 Hz, J21-22 = 11.0 Hz, CH=CH) ppm. 13C 180	
NMR (CD3OD) δ: 13.0, 22.3, 24.5, 26.7, 28.6, 28.8, 28.9, 29.4, 31.5, 33.4, 60.7, 63.2, 181	
68.8, 69.8, 70.8, 71.8, 72.2, 72.9, 73.2, 80.8, 92.3, 103.9, 129.4, 129.5, 174.0 ppm. IR 182	
(Nujol): 3404, 2951, 1735, 1711 cm-1. 183	
4b [(Z)-6’-O-tetracos-15-enoyl lactose, lactose nervonate, URB1077]. Yield: 93% 184	
(0.276 g). Mp: modification of the physico-chemical state starting from 60 °C. ESI-185	
MS: m/z 690 (M-H)–, 709 (M+NH4)+. 1H NMR (DMSO) δ: 0.86 (t, 3H, J = 6.5 Hz, 186	
CH3), 1.15–1.35 [m, 32H, (CH2)n], 1.47–1.58 (m, 2H, CH2CH2COOR), 1.94–2.04 (m, 187	
4H, CH2CH=CHCH2), 2.30 (t, 2H, J = 7.5 Hz, CH2COOR), 3.17 (ddd, 1H, J2-1 = 4.0 188	
Hz, J2-OH2 = 7.0 Hz, J2-3 = 9.5 Hz, H2), 3.27 (dd, 1H, J4-3 ≅ J4-5 = 9.5 Hz, H4), 3.33–189	
3.37 (m, 2H, H8, H9), 3.57 (dd, 1H, J3-2 ≅ J3-4 = 9.5 Hz, H3), 3.60–3.67 (m, 3H, H6a, 190	
H6b, H10), 3.68–3.77 (m, 2H, H5, H11), 4.08 (dd, 1H, J12b-11 = 4.5 Hz, J12b-12a = 11.5 Hz, 191	
H12b), 4.16 (dd, 1H, J12a-11 = 8.5 Hz, J12a-12b = 11.5 Hz, H12a), 4.20–4.27 (m, 2H, H7, 192	
OH3), 4.41 (dd, 1H, JOH6-6a ≅ JOH6-6b = 6.0 Hz, OH6), 4.54 (d, 1H, JOH2-2 = 7.0 Hz, 193	
OH2), 4.78 (d, 1H, JOH10-10 = 5.0 Hz, OH10), 4.85 (br s, 1H, OH), 4.90 (dd, 1H, J1-OH1 194	
≅ J1-2 = 4.0 Hz, H1), 5.15 (br s, 1H, OH), 5.31 (ddd, 1H, J22-23a ≅ J22-23b = 6.0 Hz, J22-21 195	
= 11.0 Hz, CH=CH), 5.34 (ddd, 1H, J21-20a ≅ J21-20b = 6.0 Hz, J21-22 = 11.0 Hz, 196	
7	
	
CH=CH), 6.33 (d, 1H, JOH1-1 = 4.0 Hz, OH1) ppm. 13C NMR (DMSO) δ: 14.4, 22.6, 197	
24.8, 27.01, 27.02, 29.0, 29.02, 29.1, 29.2, 29.22, 29.29, 29.31, 29.4, 29.50, 29.52, 198	
29.53, 29.6, 31.8, 33.8, 61.0, 63.7, 68.7, 70.2, 70.8, 71.7, 72.7, 72.9, 73.3, 81.6, 92.5, 199	
104.0, 130.1, 130.1, 173.4 ppm. IR (Nujol): 3415, 2960, 1731, 1712 cm-1. 200	
 201	
2.3 Cell culture 202	
Caco-2 cells were cultured to confluence in 75 cm3 flasks at 5% CO2 and 37 °C. Once 203	
confluent, they were detached from the flasks and seeded on filter inserts 204	
(Transwell®) at 100,000 cells/cm2. Cells were maintained at 5% CO2, 37 °C in 205	
DMEM supplemented with FBS (10%) antibiotic/antimycotic and L-glutamine, which 206	
was changed regularly (every other day). Cell growth and tight junction formation 207	
was assessed by transepitelial electrical resistance (TEER) measurements. Cell layers 208	
were used for TEER and permeability experiments following 21 days culture on 209	
Transwell inserts.  210	
 211	
2.4 MTS toxicity assay 212	
The MTS colorimetric assay was performed to evaluate the effect of surfactants on 213	
cell viability. Caco-2 cells were seeded on 96-well plates at 10,000 cells per well and 214	
cultured in DMEM for 24 h. Prior to the assay, cell medium was removed and 215	
replaced with surfactant samples at the following concentrations: 0.00625 mg/mL, 216	
0.0125 mg/mL, 0.025 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL and 217	
0.8 mg/mL in HBSS. Triton X-100 (0.1%, v/v in HBSS) and HBSS were used as a 218	
positive and negative control, respectively. Cells were incubated (at 37 °C, 5% CO2) 219	
with samples and controls for a period of 3 h. Samples (and controls) were then 220	
removed and cells washed with phosphate-buffered saline (PBS). The MTS assay was 221	
subsequently conducted according to the manufacturer’s instructions, with four 222	
repeats for each sample. 223	
The relative cell viability (%) was calculated using the following equation: 224	
 225	
  Eq. (1) 226	
 227	
 228	
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 229	
Where: S is the absorbance of the tested samples, T is the absorbance of cells 230	
incubated with Triton X-100, and H is the absorbance of cells incubated with HBSS. 231	
 232	
2.5 TEER experiments 233	
Caco-2 cell monolayers with a TEER ≥800 Ωcm2 were used in these experiments. 234	
Prior to the sample application, cell medium was removed and replaced with HBSS. 235	
Cells were equilibrated in HBSS (incubated at 37 ºC, 5% CO2) for 30 min, following 236	
which TEER was measured; this was treated as the baseline TEER. Surfactants 237	
solutions at 0.0125-0.1 mg/mL concentration range were then applied to the apical 238	
side of the cell monolayers and cells were incubated with the samples for 3 h. 239	
Chitosan at 0.1 mg/mL was employed for comparison as an example of a compound 240	
with well-documented ability to open epithelial tight junctions, and as a result, 241	
decrease TEER. TEER was measured every 30 min for 3 h in the presence of the 242	
tested surfactant samples. The samples were removed after 3 h and cells washed 243	
extensively with PBS. Cell medium was then added to both sides of the cell 244	
monolayers and cells incubated with the culture medium (DMEM) overnight. A 245	
further measurement of TEER was taken (with cells bathed in medium) 24 h 246	
following the exposure of the cells with surfactants to establish whether the changes 247	
in TEER (if any) were reversible. TEER was measured using an EVOM 248	
Voltohmmeter (World Precision Instruments, UK), equipped with a pair of chopstick 249	
electrodes. Background TEER due to the filter (~100 to 110 Ωcm2) was deducted 250	
from the measurements in all cases. All experiments were performed in triplicates. 251	
 252	
2.6 Permeability experiments 253	
FITC-OVA was used as model of a protein drug. Caco-2 cells were cultured on filters 254	
as described above and only cell monolayers with TEER ≥800 Ωcm2 were used for 255	
the purpose of this experiment. Prior to the sample application, culture medium was 256	
removed and the cell layers washed with PBS. Cells were then equilibrated in HBSS 257	
for 30-45 min. Surfactant solutions, at the final concentrations of 0.2, 0.1 and 0.05 258	
mg/mL and FITC-OVA of 100 µg/mL, respectively, in HBSS, were then applied 259	
together to the apical side of the cells. Basolateral solution was sampled (100 µL 260	
volumes) at 30, 60, 90, 120, 150 and 180 min after sample application and the 261	
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sampled volume replaced with fresh HBSS. Sampled FITC-OVA was quantified by 262	
fluorescence, using a Tecan M200 Pro plate reader. After the final sampling, the cell 263	
layers were then washed with PBS and TEER measured in order to ensure that the cell 264	
layer integrity was not compromised during the permeability experiments and that 265	
cells recover. The permeability of FITC-OVA is expressed as the apparent 266	
permeability coefficient (Papp), calculated using the following equation: 267	
 268	
					Eq. (2) 269	
 270	
Papp, apparent permeability (cm/s); ΔQ/Δt, permeability rate (amount of FITC-OVA 271	
traversing the cell layers over time); A, diffusion area of the layer (cm2); C0, apically 272	
added FITC-OVA concentration. The experiment was conducted in triplicates. 273	
 274	
2.7 Bacterial strains and culture conditions 275	
Eight reference human pathogens were used in this study, Escherichia coli O157:H7 276	
ATCC 35150, Listeria monocytogenes ATCC 7644, Salmonella enteritidis ATCC 277	
13076, Enterococcus fecalis ATCC 29212, Pseudomonas aeruginosa ATCC 9027, 278	
Staphylococcus aureus ATCC 43387, Yersinia enterocolitica ATCC 27729, and 279	
Candida albicans ATCC 14053. All the strains were routinely maintained in Tryptic 280	
Soy Agar (TSA, Oxoid, Milan, Italy) at 37 °C, while stock cultures were keep at -80 281	
°C in Nutrient broth (Oxoid) with 15% of glycerol.  282	
 283	
2.8 Determination of MICs  284	
MICs determination of lactose palmitoleate and lactose nervonate was performed by 285	
microdilution method. For the tests, each compound (1.28 mg) was dissolved in 286	
DMSO (1 mL). Several colonies of each bacterial strain were picked and inoculated in 287	
sterilized Mueller-Hinton broth (MHB) (Oxoid) (10 mL) and incubated at 37 °C for 288	
18–24 h. Bacterial suspensions were adjusted by spectrophotometer to a turbidity 289	
corresponding to 106 cfu/mL (OD610nm 0.13-0.15) and each bacterial suspension (100 290	
µL) was added in wells of the 96-well plate together with the appropriate volumes of 291	
the test solution to obtain final concentrations of 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5 292	
µg/mL. Two rows of the 96-well plate were used for positive (bacteria alone) and 293	
negative controls (MHB alone), respectively. Gentamicin (128-0.125 µg/mL) and a 294	
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standard preservative mixture (methylparaben and propylparaben, ratio 9:1) (1024-0.5 295	
µg/mL) were added as internal controls. Preliminary assays with DMSO were 296	
performed to exclude its possible bacteriostatic and/or bactericidal activity; therefore, 297	
volumes of DMSO solutions added in each well never exceeded 5% (v/v) of the ﬁnal 298	
total volume. MICs were defined as the lowest concentration of compound inhibiting 299	
the visible bacterial growth after 24 h of incubation. All the experiments were 300	
performed in duplicate. 301	
 302	
2.11 Time kill experiments against food-borne pathogens 303	
To evaluate the antimicrobial activity of lactose palmitoleate and lactose nervonate, 304	
time-kill experiments against food-borne pathogens, here represented by E. coli O157: 305	
H7 ATCC 35150, L. monocytogenes ATCC 7644, and S. enteritidis ATCC 13076, 306	
were performed. For this, pathogens strains were grown overnight in 20 mL of MHB 307	
at 37 °C and, after incubation, 500 µL (about 107 cfu/mL, as previously determined by 308	
spectrophotometer) of each pathogen suspension were incubated in 24-well culture 309	
plates with 500 µL of MBH with lactose palmitoleate or lactose nervonate at MIC and 310	
2MIC concentrations. Several wells were inoculated with 500 µL of each pathogen 311	
suspension in 500 µL of MBH as controls.  312	
At baseline, and after 3, 6 and 24 h of incubation, one aliquot of each sample was 313	
aseptically removed, serially diluted in physiological saline solution, and plated on 314	
TSA plates for colonies forming units enumeration (cfu/mL). Volumes of DMSO 315	
solution added in each well never exceeded 1% (v/v) of the ﬁnal volume. All the 316	
experiments were performed in duplicate. 317	
 318	
2.12 Statistical analysis 319	
Statistical analysis was performed using Prism version 5.0 (GraphPad Inc., USA). The 320	
assumptions for parametric test were cheeked prior to carry out the analysis. To 321	
compare the numbers of bacteria recovered in time-kill experiments after exposure to 322	
lactose palmitoleate and lactose nervonate, one-way analysis of variance (ANOVA) 323	
with Bonferroni post-test was performed; when the assumptions for parametric test 324	
were not respected, Kruskall-Wallis non parametric test with Dunn’s multiple 325	
comparison test was applied. P values < 0.05 were considered to be statistically 326	
signiﬁcant. 327	
 328	
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 329	
3. Results  330	
3.1 Cell viability  331	
Figure 1 shows the effect of tested compounds, applied within a broad dose range, on 332	
Caco-2 cell viability. Lactose palmitoleate did not display notable toxicity to Caco-2 333	
cells regardless of the applied concentration (cell viability ranged from 88% to 141%) 334	
and no dose-dependent effect was apparent. Similarly, lactose nervonate did not show 335	
a concentration-dependent effect, but with this surfactant the majority of the tested 336	
concentrations were associated with a decrease in cell viability, which was most 337	
apparent with 0.05 mg/mL.  338	
 339	
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Figure 1. Effect of lactose palmitoleate and lactose nervonate surfactants on relative Caco-2 cell 342	
viability, as determined by the MTS metabolic activity assay. Surfactants were applied at 0.00625 343	
mg/mL, 0.0125 mg/mL, 0.025 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL and 0.8 344	
mg/mL. Relative viability calculated by normalising against negative control, Hank’s Balanced Salt 345	
Solution (HBSS) and positive control, 0.1% v/v Triton X-100 in HBSS. Data shown as the mean ± SD 346	
(n=6). 347	
 348	
3.2 TEER 349	
Figure 2 shows the effect of lactose palmitoleate and lactose nervonate surfactants on 350	
Caco-2 monolayer TEER. The concentration range tested for their impact on 351	
epithelial TEER was 0.0125-0.1 mg/mL, which is in fact well below 0.8 mg/mL, the 352	
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dose found to be not toxic to Caco-2 cells (Figure 1). Chitosan was incorporated in 353	
this experiment as a TEER-lowering compound to provide a comparison.  354	
The data shows that both lactose palmitoleate and lactose nervonate decreased Caco-2 355	
monolayer TEER at all tested doses. For lactose palmitoleate, there is a sharp decrease 356	
in TEER, with maximal decrease by 62-68% of the baseline value (depending on the 357	
concentration), observed 2.5 h post application (Figure 2A). Compared to chitosan, 358	
although a lower minimal TEER compared to the surfactants is apparent with 359	
chitosan, the maximal decrease amounted to 62% of the baseline value. With lactose 360	
nervonate, a more gradual decrease in TEER was observed compared to both lactose 361	
palmitoleate and chitosan. TEER reached a minimal value 3 h post application, which 362	
equated to a drop by 41-65%, depending on the concentration (highest dose exerting 363	
the largest TEER decrease). With both surfactant compounds, TEER reversed to 364	
original (pre-application) values, confirming no long-lasting effect on cell toxicity, 365	
tight junctions and cell monolayer integrity, while the TEER of chitosan-treated cells 366	
showed partial TEER reversibility (to 64% of the baseline value).  367	
 368	
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Figure 2. Effect of lactose esters on Caco-2 cell monolayer transepithelial electrical resistance (TEER). 369	
A) Lactose palmitoleate and B) Lactose nervonate. Surfactants were applied to confluent cell 370	
monolayers at a concentration of 0.1, 0.05, 0.025 and 0.0125 mg/mL. Data are expressed as % of the 371	
baseline TEER and presented as the mean ± SD (n=3). 372	
 373	
3.3 Permeability studies 374	
The effect of surfactants lactose palmitoleate and lactose nervonate on the 375	
permeability (apparent permeability coefficient) of a model protein, FITC-OVA (Mw 376	
~45,000 Da), is shown in Figure 3 (A and B, respectively). The compounds were 377	
applied to Caco-2 monolayers at 0.2 mg/mL, 0.1 mg/mL and 0.05 mg/mL. Applied at 378	
0.2 mg/mL, lactose palmitoleate enhanced FITC-OVA permeability 11.5-fold (Figure 379	
3A). The next lower dose (0.1 mg/mL) increased FITC-OVA permeability, but this 380	
increase did not reach statistical significance. The lowest applied concentration of 381	
lactose palmitoleate did not influence FITC-OVA permeability.  382	
With lactose nervonate (Figure 3B), the highest and lowest used doses (0.2 and 0.05 383	
mg/mL, respectively) did not induce a statistically significant effect on FITC-OVA 384	
permeability. The 0.1 mg/mL dose, however, led to a 2.5-fold enhancement of FITC-385	
OVA permeability. It is not presently clear why at 0.1 mg/ml lactose nervonate 386	
induced a higher permeability than the higher dose of 0.2 mg/ml. However, this 387	
may be related to the complex relationship between surfactant concentration and 388	
their behaviour in solution (including CMC) and, in turn, interaction with the 389	
biological systems. 390	
 391	
 392	
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 394	
Figure 3. Effect of lactose esters on ovalbumin permeability across Caco-2 cell monolayers.  395	
A) Lactose palmitoleate and B) Lactose nervonate. Surfactants were applied to confluent cell 396	
monolayers at 0.2 mg/ml, 0.1 mg/mL and 0.05 mg/mL. Data are expressed as apparent permeability 397	
coefficient (Papp) and presented as the mean ± SD (n=3).  398	
 399	
3.4 Antimicrobial activities of lactose palmitoleate and lactose nervonate 400	
The antimicrobial activities of lactose palmitoleate and lactose nervonate were 401	
evaluated by determining the MIC, and subsequently carrying out time-kill 402	
experiments against food-borne pathogens. MICs of lactose palmitoleate and lactose 403	
nervonate against Escherichia coli O157:H7 ATCC 35150, Listeria monocytogenes 404	
ATCC 7644, Salmonella enteritidis ATCC 13076, Enterococcus fecalis ATCC 29212, 405	
Pseudomonas aeruginosa ATCC 9027, Staphylococcus aureus ATCC 43387, 406	
Yersinia enterocolitica ATCC 27729 and Candida albicans ATCC 14053 were tested 407	
according to the National Committee for Clinical Laboratory Standards (NCCLS) 408	
document M100-S12 method. The relative data are shown in Table 1.  409	
Lactose nervonate showed the greatest antimicrobial activity against the three food-410	
borne pathogens included in this study, Escherichia coli O157:H7 ATCC 35150, 411	
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Listeria monocytogenes ATCC 7644, and Salmonella enteritidis ATCC 13076, with 412	
MIC values of 64 µg/mL.  413	
Lactose palmitoleate showed similar MIC values of 64 µg/mL toward Escherichia 414	
coli O157:H7 ATCC 35150 and Listeria monocytogenes ATCC 7644, and a higher 415	
MIC value (128 µg/mL) towards Salmonella enteritidis ATCC 13076. The MICs 416	
values of lactose palmitoleate and lactose nervonate against the others tested 417	
microorganisms were similar to those reported against the food-borne pathogens. 418	
With regards to internal controls, gentamicin inhibited microbial growth with the 419	
lowest MIC value of 4 µg/mL for Salmonella enteritidis ATCC 13076 and the highest 420	
MIC value of 128 µg/mL for Escherichia coli O157:H7 ATCC 35150, while parabens 421	
mixture showed MIC values >1024 µg/mL for all the examined bacterial species. 422	
 423	
 424	
Table 1. MIC values (µg/mL) of the tested compounds against selected bacterial strains. 425	
 MICs (µg/mL) 
Target microrganisms Lactose palmitoleate 
Lactose 
nervonate Gentamicin Parabens 
     
E. coli O157:H7 ATCC 35150 64 64 128 >1024 
L. monocytogenes ATCC 7644 64 64 8 >1024 
S. enteritidis ATCC 13076 128 64 4 >1024 
E. faecalis ATCC 29212 64 64 64 >1024 
P. aeruginosa ATCC 9027 128 128 16 >1024 
S. aureus ATCC 43387 128 128 16 >1024 
Y. enterocolitica ATCC 27729 64 64 8 >1024 
C. albicans ATCC 10231 64 64 NA >1024 
     
 NA: not applicable 426	
 427	
Results of time–kill experiments with lactose palmitoleate and lactose nervonate at 428	
their respective MIC and 2MIC concentrations against E. coli O157:H7 ATCC 35150, 429	
L. monocytogenes ATCC 7644, and S. enteritidis ATCC 13076 are summarized in 430	
Fig. 4. 431	
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Figure 4. Antimicrobial activity of lactose palmitoleate and lactose nervonate at MIC and 2MIC 434	
concentration s in time-kill experiments against food-borne pathogens L. monocytogenes ATCC 7644 435	
(A), E. coli O157:H7 ATCC 35150 (B), S. enteritidis ATCC 13076 (C) and relative growth inhibition 436	
percentages (D). Data represent mean values of three independent experiments performed in duplicate 437	
and asterisks values statistically significant (P < 0.05, Kruskall-Wallis non-parametric test with 438	
Dunnett’s multiple comparison test). 439	
 440	
 441	
In general, the antimicrobial effect of these compounds was confirmed on the tested 442	
food-borne pathogens with a cfu/mL reduction in all the samples containing lactose 443	
palmitoleate or lactose nervonate at different concentrations (MIC and 2MIC) in 444	
comparison to the relative control samples (Fig. 4a-c). In particular, the viability of E. 445	
coli O157:H7 ATCC 35150 decreased significantly to 7.70 log cfu/mL after 24 h of 446	
incubation with lactose palmitoleate at 2MIC, compared to 9.56 log cfu/mL of the 447	
control one (Fig. 4b). Similarly, the viability of S. enteritidis ATCC 13076 was 448	
significantly reduced after 24 h of incubation with lactose palmitoleate and lactose 449	
nervonate at 2MIC with 6.95 and 6.85 log cfu/mL, respectively, compared to 9.90 log 450	
cfu/mL of the relative control (Fig. 4c). 451	
Both the tested substances induced a bacterial growth reduction during the entire 452	
incubation time, with an increased rate from 6 to 24 h. The highest values of growth 453	
inhibition, 30.88 and 29.84%, were obtained for S. enteritidis ATCC 13076 after 24 h 454	
of incubation with lactose palmitoleate and lactose nervonate at 2MIC value 455	
concentration, respectively (Fig. 4d). Similar percentages of growth inhibition were 456	
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also observed for S. enteritidis ATCC 13076 after 6 h incubation with lactose 457	
palmitoleate and lactose nervonate at MIC concentration (29.66 and 28.08%, 458	
respectively). With regards to E. coli O157:H7 ATCC 35150, growth inhibitions 459	
amounting to 22.08 and 19.47% were evidenced after 24 h incubation with lactose 460	
palmitoleate and lactose nervonate at 2MIC value concentration, respectively. Lower 461	
percentages of growth inhibition were obtained with L. monocytogenes ATCC 7644, 462	
with 15.33 and 14.85% of growth inhibition after 24 h incubation in the presence of 463	
lactose palmitoleate and lactose nervonate at 2MIC concentration, respectively (Fig. 4 464	
d). 465	
 466	
4. Discussion 467	
Different chemical or enzymatic synthetic strategies have been adopted to produce 468	
biodegradable, biocompatible and eco-friendly sugar-based materials with interesting 469	
properties, including ability to act as permeability enhancers and/or antimicrobial 470	
agents [2,17–21]. Among them, the enzymatic production of sucrose esters represent a 471	
route to obtain a promising class of compounds with multiple applications, already 472	
marketed in different fields [22,23]. Lactose palmitoleate (URB1076) and lactose 473	
nervonate (URB1077) were synthesized from palmitoleic acid (1a) or nervonic acid 474	
(1b) following a literature procedure based on a specific lipase as a catalyst, namely 475	
Lipozyme® [19], and requiring a preventive step for the protection of disaccharide 476	
derivative lactose to obtain LTA (2) [19] (Scheme 1). The final step proceeded 477	
through the deprotection of the acetalic adducts 3a,b to obtain the desired compounds 478	
4a,b (Scheme 1). 479	
 480	
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Scheme 1. Reagents and conditons: (a) toluene, 75 °C, 12 h; (b) HBF4.Et2O, CH3CN, 30 °C, 4 h. 483	
 484	
The use of the surfactant described is of potential high value due to their biological 485	
effectiveness at low concentrations and metabolism in vivo. This situation leads to 486	
non-toxic metabolites, particularly when the molecules obtained by ester bond 487	
hydrolysis are sugar and fatty acid derivatives such as those studied here.  488	
Regarding cell toxicity, it is interesting to consider that both lactose palmitoleate and 489	
lactose nervonate did not show marked toxicity to Caco-2 cells, even with a relatively 490	
high application dose (0.8 mg/mL). Furthermore, no dose-dependency was apparent. 491	
The absence of significant cell toxicity with surfactant compounds, especially at doses 492	
used here, is rare. For example, Vllasaliu et al. previously evaluated alkylmaltosides 493	
(three units sugar and linear fatty chains from C12 to C14) for their absorption 494	
enhancing property. Using a combination of methods, they demonstrated that these 495	
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surfactants produced a significant level of toxicity in bronchial epithelial cells, Calu-3, 496	
with concentration of surfactant that caused 50% cell death (IC50) values between 497	
0.0031-0.0065% w/v for the three representative compounds tested. In another 498	
example, Warisnoicharoen et al. studied the toxicity of nonionic surfactants 499	
polyoxyethylene-10-oleyl ether (C18:1E10), polyoxyethylene-10-dodecyl ether, and 500	
N,N-dimethyldodecylamine-N-oxide in bronchial cells and obtained IC50 values 501	
ranging between 0.06-0.08 mg/mL [24]. 502	
Concerning the permeability enhancement activity, a wide range of ionic and non-503	
ionic surfactants have been explored for their potential use as mucosal absorption 504	
enhancers. However, experience suggests that the use of surfactants as permeability 505	
enhancers is associated with cell toxicity [25–28], as discussed above, which severely 506	
limits their application. Of note is the emergence of alkylmaltosides, which have been 507	
clinically proposed for nasal delivery (e.g. Intraveil®). They are being explored 508	
commercially due to evidence of increased systemic bioavailability of peptides and 509	
proteins when included in nasal or ocular formulations [7,29] or when evaluated on 510	
Caco-2 and rat intestinal mucosal tissue [30].  511	
Studies exploring the use of surfactants as mucosal absorption enhancers 512	
predominantly employ relatively low molecular peptides and proteins. However, we 513	
were interested to determine whether the permeability of OVA, as an exemplar 514	
protein of ~45 kDa, is improved in an intestinal model with the compounds 515	
synthesized here. A permeability enhancement ratio of 11.5 achieved with lactose 516	
palmitoleate is remarkable considering the molecular size of OVA. Perhaps even 517	
more remarkable is the fact that a clear permeability increasing effect is not mirrored 518	
by a notable change in TEER. The combination of findings therefore points to a 519	
transcellular rather than paracellular effect with lactose palmitoleate. These findings 520	
are in agreement with a recent study by Kiss et al. [22], which reported that non-toxic 521	
concentrations of sucrose esters significantly enhanced the permeability of atenolol 522	
and fluorescein across Caco-2 monolayers. In that study, however, the surfactants 523	
caused a reduction in TEER, but, interestingly, the morphology of tight junctions 524	
remained unaffected. The authors of this study concluded that sucrose ester 525	
surfactants act as absorption enhancers through an effect on both the transcellular and 526	
paracellular routes, with a clearly demonstrated effect on elevation of plasma 527	
membrane fluidity, which was suggested as a cause of increased transcellular passage 528	
of molecules. Overall, the permeability data is important within the context of non-529	
20	
	
invasive delivery of peptide and protein therapeutics, as well as vaccine delivery 530	
(OVA is in fact a routinely used model vaccine antigen).  531	
From the pharmaceutical to the cosmetic and food fields, the need of developing safe 532	
and efficient preservatives has been growing very rapidly, particularly to find 533	
alternatives to parabens. Different sugars derivatives have been proposed to achieve 534	
this goal, starting from monosaccharides to polysaccharides as glycosidic moieties. 535	
Among them, alkylated oligomaltosides (i.e. maltoside and maltotrioside) 536	
demonstrated a valuable alternative with good antimicrobial activity explained by the 537	
inhibition of the microbial enzymatic metabolism. Due to the low solubility of these 538	
compounds the authors conducted the experiments in DMSO and the results 539	
highlighted a higher microbial inhibition for di- and polysaccharide than 540	
monosaccharide derivatives [31].  541	
In our study, the antibacterial activities of two sugar fatty acid esters, lactose 542	
palmitoleate and lactose nervonate, against several different human pathogens were 543	
evaluated. MICs of lactose palmitoleate and lactose nervonate, ranging from 64 to 128 544	
µg/mL, evidenced a greater antibacterial property compared to the parabens mixture, 545	
with MIC values >1024 µg/mL. According to other authors who have tested the 546	
antibacterial efficacy of alkylated oligomaltosides [31], our findings highlight the 547	
potential use of lactose palmitoleate and lactose nervonate sugar esters as alternative 548	
preservatives to the commonly employed ones, such as parabens.  549	
Moreover, in time-kill experiments performed toward selected food-borne pathogens, 550	
higher concentrations (2MIC values) of lactose palmitoleate and lactose nervonate 551	
were able to inhibit the growth of these bacteria, with a variable degree of 552	
antibacterial activity. For both the tested compounds, a bacteriostatic effect toward L. 553	
monocytogenes ATCC 7644 at each time point was observed, while after 24 h of 554	
incubation with lactose palmitoleate and lactose nervonate the numbers of viable E. 555	
coli O157:H7 ATCC 35150 and S. enteritidis ATCC 13076 were noticeably lower 556	
than the initial values. These data are in agreement with those of other researchers [3], 557	
which referred a strong antibacterial activity of sugar esters against food-borne 558	
pathogens. The results obtained here are interesting and encourage further studies in 559	
order to fully understand the antibacterial efficacy of lactose palmitoleate and lactose 560	
nervonate against other food-borne pathogens and their interactions with food 561	
ingredients, hence verifying their real application to control bacterial growth in food 562	
systems. 563	
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5. Conclusions 565	
The study presented here reports novel sucrose ester-based surfactant compounds with 566	
a good toxicity profile, as determined by the MTS assay and evaluation of the effect 567	
on the epithelial barrier integrity (TEER investigations). The compounds were tested 568	
for and clearly shown to display a combination of macromolecular absorption 569	
enhancing and antimicrobial properties. This is important considering the toxicity 570	
profile of the compounds demonstrated here, as these properties are often associated 571	
with unacceptable toxicity. This work therefore clearly indicates that detailed 572	
evaluation of these compounds with potential use as absorption enhancers and/or 573	
alternative preservatives is warranted in the future.  574	
 575	
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